Self-sampling to improve cervical cancer screening attendance
Cervical Cancer Prevention Using Self-sampling and Human Papillomavirus Detection
NA · The Institute of Molecular and Translational Medicine, Czech Republic · NCT04226313
This study is testing if sending self-sampling kits by mail, through gynecologists, or general practitioners can help more women in the Czech Republic get screened for cervical cancer.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 15000 (estimated) |
| Ages | 30 Years to 65 Years |
| Sex | Female |
| Sponsor | The Institute of Molecular and Translational Medicine, Czech Republic (other) |
| Locations | 1 site (Olomouc) |
| Trial ID | NCT04226313 on ClinicalTrials.gov |
What this trial studies
This trial evaluates the effectiveness of self-sampling and HPV testing to increase cervical cancer screening participation among under-screened women in the Czech Republic. It will compare three methods of providing self-sampling devices: by mail, through gynecologists, and via general practitioners. The study aims to determine the acceptability of self-sampling and its impact on screening attendance, while also analyzing sociodemographic factors. The goal is to address the low participation rates in cervical cancer screening and improve women's health outcomes.
Who should consider this trial
Good fit: Ideal candidates are women aged 30-65 who have not participated in cervical cancer screening for at least three years and reside in the Czech Republic.
Not a fit: Patients who are pregnant, have no sexual intercourse experience, or have undergone a hysterectomy will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly increase cervical cancer screening rates and reduce the incidence of cervical cancer among under-screened women.
How similar studies have performed: Previous studies in several European countries have shown success with self-sampling approaches to increase cervical cancer screening attendance.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women with age 30-65 years; for arm A women \> 65 years are allowed * Women live in the Czech Republic. * Women who have not participate in cervical cancer screening program in the Czech Republic for at least 3 years (Arm B and C). * Women with completed informed consent. * Women capable of self-sampling of cervicovaginal swab. Exclusion Criteria: * Pregnant women. * Women with no sexual intercourse experience. * Women after hysterectomy including cervix.
Where this trial is running
Olomouc
- University Hospital Olomouc — Olomouc, Czechia (RECRUITING)
Study contacts
- Study coordinator: Marian Hajduch, MD, PhD.
- Email: marian.hajduch@upol.cz
- Phone: +420 585 632 083
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cervical Cancer, Cervical Dysplasia, Human Papillomavirus Infection, human papillomavirus, HPV, self-sampling, cervicovaginal swab, cervical cancer screening